TP53 and schizophrenia: Finally, bibliographic evidence supports the proposed pathway in four aspects: (i) the implication of p53/MDM2 in the multidrug resistance process [80,81,82,83], (ii) the involvement of p53 in autophagy, a process known to be related to antipsychotic response [92,93,94,95]; (iii) the observed dysregulations of this pathway in schizophrenia patients [96,97,98], and (iv) the relationship of this pathway to negative symptoms, such as memory, learning ability impairment [99], and major depression [100].